{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:42:43Z","timestamp":1786372963946,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>\n                      This study sought to (\n                      <jats:italic toggle=\"yes\">1<\/jats:italic>\n                      ) characterize the pharmacokinetic (PK) profile of intravenous (IV) daptomycin among patients receiving continuous ambulatory peritoneal dialysis (CAPD); (\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      ) identify optimal IV CAPD dosing schemes; and (\n                      <jats:italic toggle=\"yes\">3<\/jats:italic>\n                      ) determine extent of daptomycin penetration into the peritoneal space after IV administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      A PK study was conducted among eight CAPD patients. Population PK modeling and Monte Carlo simulation (MCS) were used to identify CAPD dosing schemes providing efficacy and toxicity plasma profiles comparable with those obtained from MCS using the daptomycin population PK model derived from patients in the\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      bacteremia-infective endocarditis (SAB-IE) study. The primary efficacy exposure target was the area under the curve (AUC). For toxicity, the goal was to identify CAPD dosing schemes that minimized plasma trough concentrations in excess of 24.3 mg\/L. Finally, peritoneal cavity penetration was determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Administration of IV daptomycin 4 or 6 mg\/kg, depending on indication, every 48 h was identified as the optimal CAPD dosing scheme. This regimen provided cumulative (AUC\n                      <jats:sub>0\u201348<\/jats:sub>\n                      ) and daily partitioned (AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      and AUC\n                      <jats:sub>24\u201348h<\/jats:sub>\n                      ) plasma AUC values similar to the SAB-IE or \u201ctypical patient\u201d simulations. In addition, the proportion of patients likely to experience an elevated trough concentration in excess of 24.3 mg\/L was similar between every 48 h CAPD dosing and the referent group. Penetration into the peritoneal cavity was 6% of plasma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daptomycin 4 or 6 mg\/kg, on the basis of indication, IV every 48 h was found to be the optimal IV CAPD dosing scheme.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.08510910","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T22:45:41Z","timestamp":1299797141000},"page":"1081-1088","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis"],"prefix":"10.2215","volume":"6","author":[{"given":"Katie E.","family":"Cardone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Meola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren W.","family":"Grabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20230811","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1128\/AAC.45.6.1915-1918.2001","article-title":"In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers","volume":"45","author":"Fuchs","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-19-20230811","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1177\/089686080702702s47","article-title":"Evolution of antibiotic resistance mechanisms and their relevance to dialysis-related infections","volume":"27","author":"Wong","year":"2007","journal-title":"Perit Dial Int"},{"key":"R3-19-20230811","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/089686080202200508","article-title":"Predictors of outcome following bacterial peritonitis in peritoneal dialysis","volume":"22","author":"Krishnan","year":"2002","journal-title":"Perit Dial Int"},{"key":"R4-19-20230811","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R5-19-20230811","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-19-20230811","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-19-20230811","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R8-19-20230811","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ndt\/gfn472","article-title":"Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis","volume":"24","author":"Burkhardt","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R9-19-20230811","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/383472","article-title":"Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens","volume":"38","author":"Carpenter","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R10-19-20230811","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/00365540802613095","article-title":"Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient","volume":"41","author":"Goedecke","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"R11-19-20230811","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.ajkd.2009.02.017","article-title":"Plasma and peritoneal dialysate levels during daptomycin therapy for peritonitis","volume":"53","author":"Khadzhynov","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R13-19-20230811","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/clpt.1986.165","article-title":"Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis","volume":"40","author":"Janicke","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"R14-19-20230811","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0010-468X(79)90025-4","article-title":"A program package for simulation and parameter estimation in pharmacokinetic systems","volume":"9","author":"D'Argenio","year":"1979","journal-title":"Comput Programs Biomed"},{"key":"R15-19-20230811","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jac\/dkp289","article-title":"Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection","volume":"64","author":"Bowker","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R16-19-20230811","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg337","article-title":"Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model","volume":"52","author":"Dandekar","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R17-19-20230811","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-19-20230811","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-19-20230811","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R20-19-20230811","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1086\/647938","article-title":"Daptomycin: From the mountain to the clinic, with essential help from Francis Tally, MD","volume":"50","author":"Eisenstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R21-19-20230811","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Once-daily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-19-20230811","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insights from the Society of Infectious Diseases Pharmacists","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacotherapy"},{"key":"R24-19-20230811","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.01650309","article-title":"Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis","volume":"4","author":"Salama","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R25-19-20230811","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ndt\/gfp655","article-title":"Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients","volume":"25","author":"Salama","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R26-19-20230811","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/jac\/dkq109","article-title":"Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections","volume":"65","author":"Traunmuller","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R27-19-20230811","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/jac\/dkq118","article-title":"Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis","volume":"65","author":"Bahte","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R28-19-20230811","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/089686080902900614","article-title":"Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis","volume":"29","author":"Hassoun","year":"2009","journal-title":"Perit Dial Int"},{"key":"R29-19-20230811","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1053\/j.ajkd.2008.12.017","article-title":"Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis","volume":"54","author":"Huen","year":"2009","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201105000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:39Z","timestamp":1786369239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201105000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.08510910","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}